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DESCRIPTION of CASE
A 
58-year-old woman presented to her primary care 
physician in April 2002 complaining of troubling 
abdominal symptoms. She described abdominal 
bloating and pain with frequent diarrhoea and modest 
weight loss. There was no history of fevers or rigors. She 
had a background of irritable bowel syndrome, monoclonal 
gammopathy of uncertain significance (MGUS), ureteric 
stones, hysterectomy, and fracture of her left tibia and 
fibula. Investigations for possible inflammatory bowel disease 
in the 1980s had been negative. Investigations revealed 
normal electrolytes, renal function coeliac screen, and full 
blood count, but raised rheumatoid factor, an erythrocyte 
sedimentation rate of 26 mm/hr, and a C-reactive protein 
(CRP) level of more than 250 mg/l (Addenbrooke’s Hospital 
does not quantify CRP at levels of more than 250 mg/l). 
Because of the raised inflammatory markers, she was referred 
for further evaluation to the infectious diseases clinic at 
Addenbrooke’s Hospital.
The patient’s case was reviewed in the infectious diseases 
clinic in July 2002. A course of sulfasalazine for presumed 
inflammatory bowel disease had been commenced by 
her primary care physician, but had been stopped due to 
lack of efficacy. Examination of the patient was entirely 
unremarkable.
At This Stage, What Was Our Differential Diagnosis?
Given her symptoms and raised inflammatory markers, 
inflammatory, infectious, and malignant processes were all 
considered in the initial differential diagnosis. However, 
given the preponderance of abdominal symptoms, a diagnosis 
of inflammatory bowel disease was thought to be most likely. 
A gallium scan was arranged to investigate this possibility. The 
result showed non-specific uptake in the right iliac fossa, and 
was reported as consistent with inactivated or treated Crohn’s 
disease rather than active inflammatory bowel disease. By 
March 2003, the patient reported ongoing symptoms of 
bloating, abdominal pain, and watery diarrhoea. Weight 
loss had ceased, but her CRP remained highly elevated. As 
inflammatory bowel disease remained our main differential, 
she was referred to gastroenterology for colonoscopy, with 
biopsies taken of the ascending colon and terminal ileum. 
Colonoscopic as well as histological examination of the 
patient’s bowel was completely normal. In September 2003, 
the patient developed pain over her left sacro-iliac joint.
What Was the New Differential Diagnosis?
Raised inflammatory markers with sacro-iliac pain suggested 
sacro-iliitis, and would be consistent with past or present 
inflammatory bowel disease. Infectious and inflammatory 
causes are the most common; blood cultures and early 
morning urine specimens were sought, but failed to grow 
mycobacteria or other pathogens. Plain radiographs of the 
lumbo-sacral spine revealed no evidence of sacro-iliitis or 
fracture. Given the ongoing abdominal symptoms, imaging 
of the abdomen with ultra-sound was arranged to allow 
investigation of abscesses or masses. This showed mild fatty 
infiltration of the liver and a probable angiomyolipoma in the 
lower pole of the right kidney. 
Is MGUS Entirely Benign? Could It Account for the 
Patient’s Condition?
Re-assessment of the patient in clinic in August 2004 outlined 
the patient’s main problems as: (1) raised CRP of unknown 
aetiology, (2) back pain, and (3) MGUS. Given that MGUS 
can progress to multiple myeloma, and in view of the back 
pain, a formal diagnosis of multiple myeloma needed to be 
excluded. Urinary Bence-Jones proteins were negative, and 
serum electrophoresis again confirmed normal levels of 
immunoglobulin G (IgG) and IgA, with a monoclonal band 
in IgM of 5 g/l, unchanged since the initial diagnosis of 
MGUS in 1999. A haematology opinion was sought, and the 
patient was re-assured that her MGUS was stable, and unlikely 
to be the cause of her raised inflammatory markers.
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What Potential Diagnoses Remained?
By November 2004, the patient remained without a 
diagnosis, more than 30 months after initial presentation. 
Echocardiogram of the heart to exclude atrial myxoma was 
normal. A computerized tomography scan of the abdomen 
and pelvis was arranged to look for occult abscess or 
malignancy. A rheumatology review suggested diagnoses of 
early rheumatoid arthritis and amyloidosis. Plain radiographs 
of the hands and feet were normal, and the previous colonic 
biopsies were re-examined for evidence of amyloid deposition 
by Congo red staining, but were normal. It was at further 
review at the infectious diseases clinic in April 2005 that it 
was suggested that the elevated CRP measurements might be 
due to interference in the biochemical assay. By that time, the 
patient had had eight alternative diagnoses considered (Table 
1), and had been investigated for three years. 
The biochemistry department confirmed that there was 
indeed interference in the CRP assay due to the patient’s 
monoclonal gammopathy. This was determined on the basis 
of three observations: (1) removal of high molecular species 
by polyethylene glycol removed the interference; (2) the 
“interferent” in the patient’s serum mobilised in the same 
fraction as her monoclonal band; and (3) interference by 
the patient’s serum was also detected in the laboratory’s 
phenytoin assay (see below). Since the weight loss and 
abdominal pain had ceased, and the patient’s only remaining 
symptom was mild back pain, the patient was re-assured, and 
discharged from further follow-up.
DISCUSSION
CRP is a cyclic-pentamer acute-phase protein synthesised 
rapidly in the liver in response to inflammatory stimuli, 
especially interleukin-6. The subunits of CRP bind to a range 
of biologically significant ligands, causing activation of the 
complement cascade via the classical pathway. Measures 
of CRP are useful for the detection and assessment of 
infection, tissue injury, and inflammatory diseases [1]. 
The majority of routine methods for the detection of CRP 
use the principle of turbidimetry. Less light is able to pass 
through a turbid (cloudy) sample than a clear sample, and 
turbidimetry is the measure of this difference. The sensitivity 
of turbidimetric assays can be increased by using particle-
enhanced turbidimetric immunoassays (PETIAs). Latex 
particles, coated with anti-CRP monoclonal antibodies, 
bind CRP and agglutinate resulting in increased sample 
turbidity. The decrease in transmitted light is proportional 
to the CRP concentration. Paraprotein-induced latex particle 
agglutination also causes increased sample turbidity, and 
hence a false increase in the measured CRP concentration 
(Figure 1). This interference could be specific (i.e., limited to 
measurement of CRP only) or non-specific. In this case, the 
patient’s IgM paraprotein also interfered with measurement 
of phenytoin, but not phenobarbitone levels (both of which 
use a particle-enhanced turbidimetric inhibition assay, or 
PETINIA). No other assays in the Addenbrooke’s laboratory 
used a PETIA or PETINIA, so interference against other 
immunoassays was not determined.
Immunoassay interference is rare, with a quoted incidence 
of 0.05% to 2%, but is probably underestimated [2]. In 
one large prospective study of over 5,000 patients, the 
incidence of interference in a thyroid stimulating hormone 
immunoassay with potentially adverse clinical effect was 0.4% 
[3]. Although interference of CRP immunoassays by both 
polyclonal and monoclonal antibodies has been described 
in the clinical chemistry literature [4–7], this phenomenon 
is less appreciated in the general medical community [8]. 
Interference with immunoassays have previously led to 
extensive and sometimes invasive investigation of patients 
[3,9]. In our patient, at least eight definitive diagnoses were 
considered as part of her investigation in the out-patient 
department over a course of two years (Table 1), and 
she underwent numerous tests including endoscopy and 
multiple radiological investigations. In cases of patients with 
persistently elevated CRP levels, or other markers measured 
by immunoassay, outside of the clinical context, the possibility 
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Figure 1. Schematic Illustrating One Possible Mechanism of How 
Antibody Interferes with PETIAs
(A) In PETIAs, latex particles coated with antibody against CRP bind 
specifically to the target. This increases the turbidity of the sample, 
resulting in a decreased transmission of light, which reads as an 
increased concentration of CRP. (B) In interference by, e.g., monoclonal 
antibody, the antibody binds the anti-CRP-coated beads, increasing 
turbidity and leading to falsely elevated readings of CRP concentration.PLoS Medicine  |  www.plosmedicine.org 1052 July 2008  |  Volume 5  |  Issue 7  |  e149
of interference from paraproteins or other endogenous 
antibodies should be considered.  
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Table 1. Potential Differential Diagnoses Considered to 
Explain Elevated CRP
Date Potential Diagnosis Considered from 
Elevated CRP
August 2002 Inflammatory bowel disease
September 2003 Tuberculosis
February 2004 Ureteric stone
August 2004 Multiple myeloma
January 2005 Rheumatoid arthritis; amyloidosis; atrial 
myxoma
April 2005 Interference with CRP immunoassay
doi:10.1371/journal.pmed.0050149.t001